Mature B-Cell Lymphoma And Leukemia Study III

Other illness

• Participants known to be HIV positive (for therapeutic part of protocol, HIV participants are eligible for biology studies).

Other

• Participants from Collaborating Sites Participating in Therapeutic and Biological Objectives:
• Participants who are pregnant or lactating.
• Inability or unwillingness of research participant or legal guardian to consent.
  • Participants from Collaborating Sites Participating in Biological Objectives Only:
• Inability or unwillingness of research participant or legal guardian to consent.
• Histologic diagnosis other than a mature B-cell lymphoma as defined in the WHO classification.

• St. Jude participants and collaborating sites participating in therapeutic and biological objectives:
• Participant must have a histologic diagnosis of a mature B cell lymphoma (e.g., Burkitt lymphoma/leukemia, atypical Burkitt lymphoma, diffuse large B-cell lymphoma, mediastinal large B-cell lymphoma, mature B-cell lymphoma NOS) as defined in the WHO classification.
• Participant must be previously untreated, (no more than 72 hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation).
• Participant must be \< 22 years of age at the time of diagnosis
• For selected higher-risk CD20+ Group B and all CD20+ Group C participants receiving rituximab only (e.g., those with MLBLC, Stage III with LDH ≥ 2 times upper limit of normal (ULN), and/or bone marrow/CNS involvement: All participants who will receive rituximab must have hepatitis screening prior to enrollment. Participants whose results indicate that they are carrier of hepatitis B can still be treated per Group B or C but will NOT receive rituximab. This screening must be done for eligibility for participants who will receive rituximab, BUT the results are not needed prior to enrollment:
  • Hepatitis B immunization status (vaccination Yes or No)
  • HBsAg
  • Anti-HBs antibody
  • Anti-HBc antibody.
• All participants must have screening prior to enrollment; participants whose results indicate that they are carrier of hepatitis B can still be treated per group B and C but will NOT receive rituximab
• HIV test has been obtained within 42 days. Participants who test positive for HIV cannot be enrolled on therapeutic part of study, but are still eligible for biology studies.
• Informed consent must be obtained according to St. Jude guidelines before enrollment into study.
  • Participants from Collaborating Sites Participating in Biological Objectives Only:
• Participant must have a histologic diagnosis of a mature B cell lymphoma (e.g., Burkitt lymphoma/leukemia, atypical Burkitt lymphoma, diffuse large B-cell lymphoma, mediastinal large B-cell lymphoma, mature B-cell lymphoma NOS) as defined in the WHO classification.
• Participant must be \< 22 years of age at the time of diagnosis.
• Participant must be previously untreated (no more than 72 hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation) at the time of the diagnostic biopsy.
• Informed consent must be obtained by local PI or his/her designee according to ICH/Good Clinical Practice and local guidelines before enrollment into study.